Biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer

Biomark Med. 2020 Jul;14(11):929-932. doi: 10.2217/bmm-2020-0242.

Authors

Salvatore Fuschillo¹, Ciro Battiloro², Danilo Rocco², Luigi D Gravara³, Andrea Motta⁴, Mauro Maniscalco¹

Affiliations

¹ Istituti Clinici Scientifici Maugeri IRCCS, Pulmonary Rehabilitation Division of The Telese Terme Institute, Telese Terme, BN 82037, Italy.
² Department of Respiratory Oncology, A O dei Colli Naples 80131, Italy.
³ Università degli Studi Della Campania 'Luigi Vanvitelli', Naples 80100, Italy.
⁴ Institute of Biomolecular Chemistry, National Research Council, 80078 Pozzuoli, Naples, Italy.

PMID: 32940076
DOI: 10.2217/bmm-2020-0242

No abstract available

Keywords: biomarkers; cancer; disability; lung; outcome.

Publication types

Editorial

MeSH terms

Biomarkers, Tumor / metabolism*
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / immunology*
Carcinoma, Non-Small-Cell Lung / metabolism*
Humans
Immune Checkpoint Inhibitors / pharmacology*
Immune Checkpoint Inhibitors / therapeutic use
Lung Neoplasms / drug therapy
Lung Neoplasms / immunology*
Lung Neoplasms / metabolism*

Substances

Biomarkers, Tumor
Immune Checkpoint Inhibitors